Profile data is unavailable for this security.

About the company

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects.

  • Revenue in GBP (TTM)16.73bn
  • Net income in GBP2.66bn
  • Incorporated1992
  • Employees59.70k
  • Location
    AstraZeneca PLC1 Francis Crick AvenueCambridge Biomedical CampusCAMBRIDGE CB2 0AAUnited KingdomGBR
  • Phone+44 20 7304 5000
  • Fax+44 20 7604 8151
  • Websitehttp://www.astrazeneca.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
AZN:LSE since
Daiichi Sankyo Co LtdRumoured31 Aug 201731 Aug 2017Rumoured9.69%--
Circassia Pharmaceuticals Plc-Tudorza US Commercial RightsAnnounced17 Mar 201717 Mar 2017Announced0.38%--
Data delayed at least 20 minutes, as of Dec 14 2017 16:36 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Grifols SA4.35bn571.12m15.11bn16.81k29.424.7220.493.530.84060.84066.375.240.42261.419.19292,030.605.545.726.106.4749.1549.6313.1012.821.394.330.628118.542.9317.662.5061.0712.85--
Lonza Group AG4.44bn340.00m19.15bn10.34k46.723.69--4.425.645.6474.4471.450.5586----437,907.
Shire PLC11.13bn1.22bn33.39bn23.91k28.321.3911.813.081.331.3312.1527.020.2161.085.42465,641.102.389.022.6611.0869.7078.9111.0022.380.51796.460.386710.5477.6121.73-54.88-6.9526.6014.60
AstraZeneca plc16.73bn2.66bn60.94bn59.70k23.536.0714.023.742.102.1013.218.140.34851.464.46280,195.805.365.717.257.8981.6780.6915.3712.740.7243.900.5361108.39-6.90-7.2923.86-18.8112.284.86
GlaxoSmithKline plc30.13bn2.34bn63.33bn99.83k27.6749.9712.392.150.47510.47516.140.26310.51261.684.43301,852.204.859.918.8215.2569.3069.119.4517.670.437211.520.797690.6616.580.3639-89.17-29.4212.112.71
Sanofi SA36.40bn4.59bn92.44bn106.86k20.80--14.742.603.617.1528.65--------340,635.80--4.36--5.1168.4668.4612.6212.89------86.48-0.4389-0.2005-0.3627-
Novo Nordisk A/S113.28bn38.58bn645.68bn41.66k21.8018.0015.785.8515.4815.4845.4418.751.221.216.782,698,911.0041.6537.7978.3263.0384.2483.9334.0531.030.927746.630.005547.823.5711.008.7917.2719.9322.10
Data as of Dec 14 2017. Currency figures normalised to AstraZeneca PLC's reporting currency: UK Pound GBX

Institutional shareholders

22.71%Per cent of shares held by top holders
HolderShares% Held
BlackRock Investment Management (UK) Ltd.as of 31 Jan 201746.07m3.64%
Capital Research & Management Co. (World Investors)as of 10 Aug 201738.60m3.05%
Wellington Management Co. LLPas of 01 Nov 201737.19m2.94%
The Vanguard Group, Inc.as of 01 Nov 201733.94m2.68%
Legal & General Investment Management Ltd.as of 01 Nov 201727.13m2.14%
Norges Bank Investment Managementas of 01 Nov 201726.80m2.12%
Woodford Investment Management Ltd.as of 01 Nov 201724.88m1.97%
Dodge & Coxas of 01 Nov 201720.37m1.61%
Threadneedle Asset Management Ltd.as of 01 Nov 201717.49m1.38%
BlackRock Fund Advisorsas of 01 Nov 201715.06m1.19%
More ▼
Data from 31 Dec 2016 - 30 Sep 2017Source: FactSet Research Systems Inc.
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.